The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23271487.
- Also identified by DOI 10.1038/ki.2012.364.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nephropathy progression is slowed and cardiovascular events reduced in patients with stage 3 or higher chronic kidney disease when blood pressure is controlled using combinations of renin-angiotensin system (RAS) blockers with dihydropyridine calcium channel blockers or diuretics. We discuss a trial comparing high-dose RAS blockade with lower-dose RAS blockade combined with a dihydropyridine calcium channel blocker. The primary outcome was cardiovascular events. The combination group had better blood pressure control and fewer total events.
Medical subject headings
- Angiotensin Receptor Antagonists
- Calcium Channel Blockers
- Cardiovascular Diseases
- Hypertension
- Renal Insufficiency, Chronic